1d:I[2890,["266","static/chunks/870fdd6f-4fcc92c129a57d11.js","970","static/chunks/970-91a3a37cc668faba.js","857","static/chunks/857-3b2a1421afa266d2.js","965","static/chunks/app/podcasts/episode/%5BpodcastEpisodeGuid%5D/page-e939c6b91b4a25d4.js"],"default"] 1e:I[1318,["266","static/chunks/870fdd6f-4fcc92c129a57d11.js","970","static/chunks/970-91a3a37cc668faba.js","857","static/chunks/857-3b2a1421afa266d2.js","965","static/chunks/app/podcasts/episode/%5BpodcastEpisodeGuid%5D/page-e939c6b91b4a25d4.js"],"default"] 1f:T504,For the last 50 years, the government has classified Marijuana as a schedule one drug.

Last Tuesday, Attorney General Merrick Garland did initiate the process to reclassify marijuana as a schedule three drug. Those substances are considered by the Drug Enforcement Agency to have moderate to low potential for physical and psychological dependence.

This recommendation does not make marijuana legal at the federal level. But for the first time, the government is acknowledging marijuana's potential medical benefits.

We discuss what this move means for marijuana research, and drug policy more broadly.

Want to support 1A? Give to your local public radio station and subscribe to this podcast. Have questions? Connect with us. Listen to 1A sponsor-free by signing up for 1A+ at plus.npr.org/the1a.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

‌

Episode description

What Reclassifying Marijuana Could Mean For Research And Drug Policy

Episode description